Aurobindo Pharma Limited
https://www.aurobindo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aurobindo Pharma Limited
Assertio Targets Febrile Neutropenia Drug In Spectrum Buyout Deal
It remains unclear whether Rolvedon will achieve hoped-for sales milestones in a deal that Assertio said was part of a growth strategy emphasizing product and business acquisitions.
Will ViiV’s Regulatory Stance Delay Access To Cabotegravir Despite MPP Deal?
Scrip looks at the contours of MPP’s recent sub-licensing deal for ViiV Healthcare’s cabotegravir with Cipla, Aurobindo and Mylan, along with pricing dynamics and precedents to evaluate a few barriers to access
Three Firms Sign Up With MPP For Long-Acting Cabotegravir
Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – have signed licensing agreements with the Medicines Patent Pool that will allow them to produce versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis.
Three Firms Sign Up With MPP For Long-Acting Cabotegravir
Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – have signed licensing agreements with the Medicines Patent Pool that will allow them to produce versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Acrotech Biopharma, LLC
- APL
- Glaxo (India)
- TL Biopharmaceutical AG.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice